A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE PHARMACOKINETIC INTERACTIONS BETWEEN PF-07976016 AND PF-06882961 IN OTHERWISE HEALTHY ADULT PARTICIPANTS WITH OVERWEIGHT OR OBESITY

The purpose of this study is to see how two study medicines, PF-07976016 and danuglipron, taken together affect the level of each other in the blood of participants who have overweight or obesity.
The total number of weeks of the study is up to approximately 22 weeks (5.5 months).

开始日期2025-03-13

申办/合作机构

Pfizer Inc.

NCT06541678

/ Active, not recruiting临床1期

A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Effect of Itraconazole and Cyclosporine on the Single-Dose Pharmacokinetics of Danuglipron in Healthy Adult Participants

The purpose of this study is to see how single dose of cyclosporine and multiple doses of itraconazole affect the level of the study medicine danuglipron in the blood of healthy adult participants. The information from this study may inform how danuglipron will be used in the future with medicines like cyclosporine and itraconazole.

开始日期2024-12-23

申办/合作机构

Pfizer Inc.

NCT06567327

/ Completed临床1期

A Two-Part Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Multiple Dose Pharmacokinetics of Danuglipron Following Oral Administration and The Effects of Steady-State Danuglipron on the Pharmacokinetics of Single Oral Dose of Atorvastatin and Rosuvastatin in Otherwise Healthy Adult Participants With Overweight or Obesity

The purpose of this study is to learn the following about the study medicine, danuglipron, after multiple days of dosing in healthy adults who are overweight or obese:
* how the study medicine, danuglipron, is taken up into the blood
* if the study medicine, danuglipron, changes how the body processes other study medicines (Atorvastatin and Rosuvastatin)
* about the safety and tolerability of danuglipron
The study will take place in 4 Cohorts (groups). The total number of weeks of the study is about 23 (about 6 months) for Cohort 1 and 22 weeks (about 5.5 months) for Cohort 2, 21 weeks (about 5 months) for Cohort 3 and 20 weeks (about 5 months) for Cohort 4.

开始日期2024-08-28

申办/合作机构

Pfizer Inc.

100 项与 Danuglipron 相关的临床结果

登录后查看更多信息

100 项与 Danuglipron 相关的转化医学

登录后查看更多信息

100 项与 Danuglipron 相关的专利（医药）

登录后查看更多信息

项与 Danuglipron 相关的文献（医药）

2025-05-03·Journal of biomolecular structure & dynamics

Discovery of non-peptide GLP-1r natural agonists for enhancing coronary safety in type 2 diabetes patients

Article

作者: Iranshahi, Mehrdad ; Azimi, Sabikeh G. ; Sadeghi-Aliabadi, Hojjat ; Hadizadeh, Farzin ; Rajabian, Fatemeh ; Shakour, Neda ; Hoseinpoor, Saeideh

This study explores the computational discovery of non-peptide agonists targeting the Glucagon-Like Peptide-1 Receptor (GLP-1R) to enhance the safety of major coronary outcomes in individuals affected by Type 2 Diabetes. The objective is to identify novel compounds that can activate the GLP-1R pathway without the limitations associated with peptide agonists. Type 2 diabetes mellitus (T2DM) is associated with an increased risk of cardiovascular disease (CVD) and mortality, which is attributed to the accumulation of fat in organs, including the heart. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are frequently used to manage T2DM and could potentially offer cardiovascular benefits. Therefore, this study examines non-peptide agonists of GLP-1R to improve coronary safety in type 2 diabetes patients. After rigorous assessments, two standout candidates were identified, with natural compound 12 emerging as the most promising. This study represents a notable advancement in enhancing the management of coronary outcomes among individuals with type 2 diabetes. The computational methodology employed successfully pinpointed potential GLP-1R natural agonists, providing optimism for the development of safer and more effective therapeutic interventions. Although computational methodologies have provided crucial insights, realizing the full potential of these compounds requires extensive experimental investigations, crucial in advancing therapeutic strategies for this critical patient population.

2025-04-10·JOURNAL OF MEDICINAL CHEMISTRY

Discovery of New Difluorocyclobutyl Derivatives as Effective Glucagon-Like Peptide-1 Receptor Agonists with Reduced hERG Inhibitory Activities

Article

作者: Zhang, Jinzhu ; Wang, Jianghai ; Shao, Shuai ; Zhong, Yongqing ; Wang, Guojian ; Huang, Yun ; Tang, Xinyi ; Ma, Zhongjun ; Ding, Wanjing ; Lou, Jinfang ; Li, Yuanyuan ; Miao, Lei ; Xu, Sicong ; Lei, Shaowei

Danuglipron (PF-06882961), a small-molecule agonist of the glucagon-like peptide-1 receptor (GLP-1R) developed by Pfizer, has shown significant potential to reduce blood glucose levels and weight in patients with type 2 diabetes mellitus. However, it has moderate hERG inhibitory activities (IC₅₀ = 4.3 μM), potentially conferring a risk for cardiac toxicity. Here, we report a new class of difluorocyclobutyl derivatives that can be used to reduce the potential hERG inhibition caused by the piperidine ring of danuglipron. After in vitro and in vivo screening, compound 73 was found to be the most potent GLP-1R agonist, with an EC₅₀ of 0.048 nM. Furthermore, compound 73 showed preferable absorption and excellent β-arrestin pathway selectivity compared with danuglipron. In the glucose tolerance test, compound 73 effectively inhibited elevated blood glucose levels. These results indicate that compound 73 is a promising GLP-1R agonist.

2025-04-01·DIABETES OBESITY & METABOLISM

Anti‐diabetic effects of GLP‐1 receptor agonists on obese and overweight patients across diabetes status, administration routes, treatment duration and baseline characteristics: A systematic review

Review

作者: Tan, Benjamin Y. Q. ; Poh, Kian Keong ; Kong, William K. F. ; Wong, Hon Jen ; Lin, Norman H. Y. ; Eng, Pei Chia ; Yeo, Leonard L. L. ; Sia, Ching‐Hui ; Chan, Mark Y. ; Toh, Keith Zhi Xian ; Teo, Yao Hao ; Dalakoti, Mayank ; Teo, Yao Neng ; Yeo, Brian S. Y.

Abstract:

Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are increasingly used for anti‐obesity indications. However, little is known of the comparative effect of GLP‐1 RAs and their glycemic impact across the different routes of administration, diabetic statuses and durations of prescription. PubMed, EMBASE and CENTRAL were searched from inception to 13 February 2024. Only randomised controlled trials were included in this systematic review and meta‐analysis. Adults aged above 18 years old, who were in the overweight/obesity range, with or without type 2 diabetes mellitus (T2DM) were included. Baseline characteristics and changes in glycated haemoglobin (HbA1c) and fasting plasma glucose (FPG) were obtained. GLP1‐RAs demonstrated an overall reduction in HbA1c of −0.72% (95% confidence interval [CI] −0.79 to −0.65, p < 0.01) and in FPG of −1.00 mmol/L (95% CI −1.16 to −0.84, p < 0.01). HbA1c reduction in pre‐DM patients was −0.44% (95% CI −0.54 to −0.18, p < 0.01). Patients who were followed up for more than a year experienced a smaller reduction of HbA1c. Meta‐regression showed that the GLP‐1 RAs are more efficacious at higher HbA1c and lower body mass index. Overall, GLP‐1 RAs consistently led to a significant reduction in HbA1c at −0.72% and FPG at −1.00 mmol/L. These effects may be equally efficacious in pre‐DM patients with obesity and those at lower BMI. With pre‐DM and obesity being risk factors for metabolic syndrome, these findings may provide newer perspectives in expanding indications for GLP‐1 RA initiation.

232

项与 Danuglipron 相关的新闻（医药）

2025-06-21

·Firstwordpharma

ADA25: Lilly's oral GLP-1 dodges side effect minefield that sunk Pfizer drug

Eli Lilly detailed safety results for its oral GLP-1 asset orforglipron at the American Diabetes Association (ADA) meeting Saturday, highlighting the absence of liver toxicity, a problem that forced Pfizer to abandon its rival pill earlier this year."This convenient once-daily pill with no restrictions on food and water intake could be an option for millions of people with type 2 diabetes who prefer oral medications over injectables," said Jeff Emmick, Lilly's head of product development. "The positive ACHIEVE-1 results position orforglipron as a potential treatment option with meaningful A1C and weight reduction, and a safety profile similar to injectable GLP-1 therapies."The Phase III study is evaluating once-daily doses of orforglipron (3 mg, 12 mg, and 36 mg) as monotherapy in 559 adults with type 2 diabetes who have not achieved adequate glycaemic control through diet and exercise alone. Toplined earlier this year, patients taking orforglipron saw average reductions in HbA1c between 1.3% and 1.6% after 40 weeks, compared to just 0.1% for those on placebo, meeting the primary endpoint.On the key secondary endpoint of weight loss, patients receiving the 36-mg dose shed an average of 16 pounds, or up to 7.9% of their body weight. Lilly noted that weight loss did not appear to have plateaued by week 40, indicating the possibility for more reductions over time.Cardiometabolic gains"Beyond glycaemic control and bodyweight reduction, we observed reductions in cardiometabolic risk factors, including lipid levels, waist circumference, and systolic blood pressure, findings that indicate a favourable cardiovascular risk profile," researchers wrote in an NEJM paper, which was published Saturday.However, safety remains a central focus, with discontinuation rates and overall tolerability likely to serve as key measures for a therapy meant to be an option for chronic dosing.Lilly reiterated Saturday that orforglipron's overall safety profile in ACHIEVE-1 was consistent with the GLP-1 class as a whole, with gastrointestinal (GI) side effects such as diarrhoea (occurring in 19% to 26% of patients), nausea (13% to 18%), and dyspepsia (11% to 20%) being the most common. The events were generally mild-to-moderate and occurred mainly during dose escalation, researchers wrote.Gradual dosing escalationTo help minimise GI side effects seen in earlier studies, Lilly opted for a gradual dose-escalation strategy, starting with a lower dose and increasing every four weeks.Discontinuation rates due to side effects ranged from 4.4% to 7.8% across orforglipron doses, compared to 1.4% with placebo, and no cases of severe hypoglycaemia or liver safety concerns were reported. The incidence of elevated liver enzymes – three times the upper limit of normal or higher – was similar across all trial groups. In all orforglipron-treated participants, these levels returned to normal or near baseline while they were still receiving the drug, researchers wrote.Pfizer's withdrawal of danuglipron in April due to liver safety concerns had cast a shadow over the entire class of oral small-molecule GLP-1 agonists.Obesity results in Q3Lilly expects to report topline results from ACHIEVE-2, comparing orforglipron to AstraZeneca's SGLT2 inhibitor Farxiga (dapagliflozin), and ACHIEVE-3, comparing it to Novo Nordisk's oral semaglutide, later this year. The company also plans to share results from ATTAIN-1 and ATTAIN-2, evaluating orforglipron for weight management, in the third quarter.

临床3期临床结果

2025-05-20

·研发客

70%停药，口服成为GLP-1下一个决胜点？

// •GLP-1产品已经一只脚迈入口服时代；•使用GLP-1受体激动剂的患者在1年时有53.6%停药，2年时有72.2%停药；•小分子GLP-1受体激动剂的开发是非常具有挑战的药物化学项目；•礼来正在开展一项注射+口服的长期续贯治疗研究；•GLP-1口服赛道已经站了不少中国企业，并达成多起交易。有时候，即便是极其强调科学性的药物开发，也不得不感叹命运的翻云覆雨手。上周五（5月16日），诺和诺德宣布首席执行官周赋德（Lars Fruergaard Jørgensen）将离任的消息。援引FiercePharma的说法，更换CEO是因为“weight of market pressure”。而就在一个月前，礼来的口服小分子GLP-1产品orforglipron 3期临床试验ACHIEVE-1获得积极结果，像一把利剑刺中了诺和诺德要害。几乎同一时间，由于在安全性方面闯关失败，辉瑞宣布终止口服GLP-1受体激动剂danuglipron的临床开发。没有人知道辉瑞在这一时刻的扼腕，就像没人知道它再度重启临床试验时的决心。随着诺和诺德口服版减重司美格鲁肽Wegovy（25mg）4月21日美国上市申请获得受理，一个新故事的雏形正在展开：口服产品将如何搅动GLP-1的天下？小分子与多肽掰手腕实际上，GLP-1产品已经一只脚迈入口服时代。早在2019年，司美格鲁肽口服降糖版Rybelsus获FDA批准。2025年Q1，司美格鲁肽为诺和诺德打下了557.76亿丹麦克朗（约合78.64亿美元）的江山，成为今年第一季度的新药王。其中，降糖口服版Rybelsus卖出了56.95亿丹麦克朗（约8.03亿美元）。作为GLP-1的开山者，口服版司美格鲁肽利用SNAC吸收促进剂创新技术，越过了多肽类药物在生物利用度上的先天缺陷。那么，当礼来的orforglipron交出3期临床积极结果的时候，给诺和诺德带来的是危机，还是高手在山顶相逢的惺惺相惜？礼来公布的信息显示，在 ACHIEVE-1 研究中，orforglipron达到主要终点，即40周时，经orforglipron治疗后糖化血红蛋白（A1C）的降幅显著优于安慰剂组，A1C自8.0%的基线平均降低1.3%至1.6%（使用有效性估计目标）。同时，在关键次要终点，超过65%的患者接受最高剂量的orforglipron后A1C值降至≤6.5%，低于美国糖尿病协会定义的糖尿病阈值。在另一个关键次要终点，接受orforglipron的患者在最高剂量下平均减重7.3kg（7.9%），鉴于患者在研究结束时尚未达到体重平台期，可能表明尚未实现完全减重。诺和诺德为了证明司美格鲁肽口服剂与注射剂一样安全有效，开展了PIONEER系列3期临床试验。结果显示，在所有分组中，26周时，口服司美格鲁肽组比安慰剂组、恩格列净组或西格列汀组都显示了更大的糖化血红蛋白降低效果，与利拉鲁肽组大体持平。达到美国糖尿病协会推荐的降低糖化血红蛋白水平至7.0%（53 mmol/mol）的患者比例，口服司美格鲁肽组（7mg，42%~69%；14mg，55%~77%）高于安慰剂组（7%~31%）和其它对照药物组（25%~62%）。拓展阅读零的突破：口服司美格鲁肽的故事“一般情况下，大分子总是比不过小分子的，这就是为什么在大分子药物成功上市之后，总是会有人继续寻找小分子替代。但是反过来，从来没有人想用大分子去替代小分子。如果只看口服的生物利用度，小分子具有绝对优势。尽管这仍旧是药物化学中的一个难题，却是一个可以被攻克的难题。这是药物开发者的共识。”曾在默沙东参与糖尿病药物西格列汀研发的梁贵柏博士说。“而半衰期正好反过来。大分子药物有很多每周一次、每月一次，甚至每半年一次注射，诺和诺德的司美格鲁肽长达160个小时。小分子要做到每周一次很难。但是口服药物没有必要，每天一次是最理想的，患者依从性最好。”梁贵柏分享了他对于口服小分子和多肽类产品各自优劣的看法。安全性可能是小分子药物很难绕过的潜在风险。“小分子的毒副作用很难预见，绝大多数来源于分子本身。药物化学的解决方法是换一个化学结构不一样的先导去做优化。但是，小分子GLP-1受体激动剂很难找到好的lead。如果礼来的orforglipron 在药效与副作用方面没有明显的短板，这是一个可遇不可求的分子，其中也包括一部分运气。”orforglipron 最早由中外制药（Chugai Pharmaceutical）发现，2018年礼来以5000万美元获得这款产品的开发和商业化权益。据礼来公布的信息，orforglipron 的结构复杂，为保证药效，研发者设计开发的分子量为882.96，已接近小分子药物分子均量的上限（1000），从起始物料到制备orforglipron原料药共需要28步反应。这显然增加了抄作业的难度。回过头来看辉瑞的danuglipron，从一开始就不被业内看好，硬着头皮重启临床2期，结局可想而知。不知道它的追随者们在眼下这个十字路口将如何选择。当然，这也不是辉瑞第一次在口服GLP-1产品上折戟，前有lotiglipron因转氨酶升高的原因，于2023年停止开发。停药的情况明显今年1月，美国医学会旗下期刊JAMA Network Open刊登了一篇研究报告：一项针对125474名使用GLP-1受体激动剂患者的队列研究显示，在两年内，共有81919名患者停用了GLP-1受体激动剂。考虑到删失情况，1年时有53.6%的患者停药，2年时有72.2%的患者停药。其中，2型糖尿病患者的停药率更低（1年时为46.5%，2年时为64.1%）；而无2型糖尿病的患者在1年时停药率为 64.8%，2年时为84.4%。对此，哈佛医学院糖尿病、肥胖症与技术领域负责人Robert Gabbay博士在其社交媒体上表示，“尽管 GLP-1 类药物在减重方面效果显著，但这项研究发现，65%因肥胖而服用此类药物的患者在一年内就停止用药。目前没有很好的数据来解释这一现象。推测可能是多种因素共同作用的结果，包括成本和获取途径、副作用、无效（很多病例可能没有意识到往往需要数月才能显著减重）、用药的方便程度。”来源|JAMA Network OpenStructure Therapeutics CEO Raymond Stevens在近期的一次媒体采访中同样提到，“85%使用GLP-1患者在两年内停药，这是否暗示了口服产品将迎来全面超车？”信达生物高级副总裁钱镭博士在接受研发客采访时，提出了自己的观点。他认为，口服药和注射药物一直是“五五开”局面，有一部分人更倾向于注射类药物，一部分人选择口服。“小分子和注射类药物各自都有优缺点。前者成本低，服用方便，但很容易有脱靶风险，导致肝脏损伤。并且，容易与其他药物互相影响。注射产品成本高，而且注射治疗可能会影响顺应性。实际上，一周一次的注射治疗已经相当方便，而未来一个月一次的治疗药物顺应性会更好。当然，注射产品另一个优势是靶向精确，不容易脱靶，安全性和疗效目前来看都优于小分子。”钱镭表示。至少礼来并没有放慢注射类产品的推进速度。就在两天前，礼来公布了替尔泊肽与司美格鲁肽头对头研究（SURMOUNT-5研究）的详细结果。在第72周时，替尔泊肽达到主要终点和所有五个关键次要终点，再次叫板司美格鲁肽。拓展阅读礼来公布头对头详细结果替尔泊肽全面优于司美格鲁肽“实际上，礼来正在开展一项研究，使用替尔泊肽把体重降下来之后，再以口服小分子药物长期续贯治疗，这也是一个非常合理的思路。”钱镭透露。在口服的路上狂奔距离辉瑞宣布danuglipron停止开发已经过去一个月。这一消息一度让Structure Therapeutics和Viking在二级市场收获了不小的涨幅。两家公司手中各自握有小分子口服GLP-1在研产品。Structure的创始人及CEO Raymond Stevens对自家的产品颇为自信。他认为，2025 年将是所有口服GLP-1小分子药物在肥胖及相关疾病治疗领域的变革之年。公司在 2024年财报中提到，小分子口服GLP-1产品aleniglipron 的ACCESS 和 ACCESSⅡ 两项研究已全部招募完毕，预计将于2025年底公布顶线数据。毫无疑问，这个跑道上已经站了不少中国企业，并达成了多起交易。其中，诚益生物的ECC5004授权给了阿斯利康，获得6000万美元首付款。这款产品应该走的是礼来orforglipron的技术路线。翰森制药的HS10535也在这条跑道上，已授权给默沙东，并获得了1.12亿美元预付款。箕星药业从闻泰医药引入了一款GLP-1小分子产品。先为达生物则在今年初与Verdiva Bio达成超24亿美元授权交易，这家公司的管线中也有一款小分子GLP-1产品。今年3月，恒瑞医药已正式启动其自主研发的口服GLP-1受体激动剂HRS-7535的3期临床研究，用于超重或肥胖人群减重适应症。华东医药的HDM1002（conveglipron），已完成体重管理适应症临床3期研究首例受试者入组。信达生物布局了口服小分子GLP-1、GIP抗体偶联GLP-1/GCG受体双激动剂、PCSK9偶联GIP/GCG/GLP-1三靶点激动剂。此外，锐格医药、德睿智药、海思科、信立泰、歌礼制药等公司的产品处在不同临床阶段。随着新选手的不断加入，会不会有更多的黑马胜出？“其实，小分子药物开发门槛低，大家都觉得自己有能力做，表面上看竞争会非常激烈。但真正有实力的并不多。小分子GLP-1受体激动剂的开发是非常具有挑战的药物化学项目，这跟GLP-1受体的结构和活化机理有关。成功的关键是一个成药性好的先导化合物。目前大家的方向是想办法绕过orforglipron的专利，争取差异化。减肥药物的市场足够大，应该可以容得下不少差异化的小分子药物。在这个过程中，AI可能会发挥它的价值，帮助大家找到更好的分子。”梁贵柏说。当然，辉瑞应该不会甘心放弃这个还在膨胀的市场，不知道它会在中国淘到哪块“金子”。编辑 | 姚嘉yao.jia@PharmaDJ.com 总第2439期访问研发客网站，深度报道和每日新闻抢鲜看www.PharmaDJ.com

临床3期临床结果上市批准

2025-04-30

·ETPharma

Pfizer leans on cost cuts to offset falling revenue

Bengaluru: Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research operations, highlighting its operational efficiency even as it reported lower first-quarter revenue due to declining sales of its COVID-19 treatment Paxlovid. Chief Executive Albert Bourla, speaking on a conference call with investors, said the drugmaker's story over the next three years would not be one of strong revenue growth, given looming patent expirations on top products, but rather one of earnings growth. The company reaffirmed its full-year forecast, and shares were up nearly 4 per cent. Pfizer also said it had measures in place to mitigate the impact of potential tariffs on pharmaceuticals by the Trump administration, including possibly shifting some production to existing facilities in the United States. "We have huge manufacturing capacity right now in the U.S., particularly for everything that is injectable," Bourla said. "If there is a need, it's clearly there, and without the need to build new facilities." Pfizer has 10 manufacturing sites and two distribution centers in the United States, employing nearly 10,000 people. While the rates and timing of tariffs on the pharma sector are unclear, analysts expect that companies will have to absorb any near-term costs if they are imposed. Washington has launched an investigation into the industry, laying the groundwork for possible levies. Bourla in an interview said the industry is hoping the Trump administration will focus more on medicines like those the World Health Organization has designated as essential, which tend to be off-patent and produced mostly in China and India. "I think that's where the problem is. It's not if an obesity drug is made in Ireland," he said. LEANING ON COST SAVINGS The company said it now expects about $7.7 billion in savings by the end of 2027 from its cost-cutting programs. That includes an additional $500 million in R&D savings, which at least two investors said could reflect Pfizer's recent decision to stop development of its experimental weight-loss pill danuglipron. "The cost savings are real, it does help drive better bottom line performance," said Brian Mulberry, portfolio manager at Zacks Investment Management, which owned 2.44 million Pfizer shares at the end of 2024. "We just want to know where that top-line growth is going to come from." Not from COVID antiviral Paxlovid, apparently. Sales of the two-drug treatment were $491 million, well short of analysts' already diminished expectations of $794.3 million, according to LSEG data. Analysts significantly cut their Paxlovid sales expectations in recent weeks due to a relatively small winter wave of COVID-19 in the U.S. On an adjusted basis, Pfizer earned 92 cents per share in the first quarter, topping analysts' expectations by 26 cents, helped by cost cuts and a lower tax rate. Despite the earnings beat, Pfizer is still forecasting a full-year adjusted profit of $2.80 to $3.00 per share on revenue of $61 billion to $64 billion. CFO David Denton said Pfizer was "currently trending toward the upper end" of its profit forecast. Revenue in the quarter fell 8 per cent from a year ago to $13.72 billion and missed analysts' expectations of $13.91 billion. Potential tariffs could add to existing pressure for Pfizer. Investors have been pushing the company to bring new drugs to market that could make up for revenue likely to be lost from some top-selling medicines nearing the end of patent protection. Zacks' Mulberry said the company has done well at becoming more productive on the manufacturing side. "That's where they're finding a bulk of the savings at this point," he said, "but I don't see the next kind of really big pop in revenue." Even the drugs that outperformed Wall Street expectations in the first quarter face headwinds. Sales of its heart disease drug, sold under the brand names Vyndaqel and Vyndamax, were $1.49 billion, above estimates of $1.29 billion. But the company said it is already seeing the impact of new competition, which it expects to continue through the year. Pfizer's vaccine business could also face greater regulatory scrutiny under the new Health Secretary Robert F. Kennedy Jr., a longtime vaccine skeptic. COVID vaccine Comirnaty, which Pfizer makes with German partner BioNTech, brought in sales of $565 million. Analysts were expecting $331.7 million for the shot in the first quarter. (Reporting by Bhanvi Satija and Christy Santhosh in Bengaluru and Michael Erman in New York; Editing by Anil D'Silva and Bill Berkrot)

疫苗

100 项与 Danuglipron 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11910	-	-	DB16043

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肥胖	临床2期	美国	Pfizer Inc.	2021-01-06
2型糖尿病	临床2期	美国	Pfizer Inc.	2019-10-15
2型糖尿病	临床2期	保加利亚	Pfizer Inc.	2019-10-15
2型糖尿病	临床2期	加拿大	Pfizer Inc.	2019-10-15
2型糖尿病	临床2期	匈牙利	Pfizer Inc.	2019-10-15
2型糖尿病	临床2期	波兰	Pfizer Inc.	2019-10-15
2型糖尿病	临床2期	斯洛伐克	Pfizer Inc.	2019-10-15
2型糖尿病	临床2期	韩国	Pfizer Inc.	2019-10-15
2型糖尿病	临床2期	中国台湾	Pfizer Inc.	2019-10-15
肝损伤	临床1期	美国	Pfizer Inc.	2020-12-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04889157 (CTgov)	临床1期	2型糖尿病	20	Placebo	衊鹹願顧蓋衊築繭廠醖 = 夢鹹範廠壓艱糧鏇壓鏇選淵夢艱鬱鑰範範壓顧 (壓顧衊襯構鏇製膚遞憲, 醖網衊構構衊觸餘鏇壓 ~ 選窪網壓繭衊選壓獵壓) 更多	-	2024-10-01
NCT04616027 (CTgov)	临床1期	2型糖尿病	42	PF-06882961 (Healthy and Normal Renal Function)	繭膚餘遞蓋窪構願鏇鏇(鬱獵壓餘獵廠鹽願鑰積) = 鬱鹽衊醖窪鬱鏇衊壓淵夢齋繭網遞鏇構糧窪齋 (襯淵顧蓋壓蓋鑰艱餘鬱, 28) 更多	-	2024-05-10
				PF-06882961 (T2DM Normal Renal Function)	繭膚餘遞蓋窪構願鏇鏇(鬱獵壓餘獵廠鹽願鑰積) = 窪齋衊繭築觸鹹淵鑰簾夢齋繭網遞鏇構糧窪齋 (襯淵顧蓋壓蓋鑰艱餘鬱, 58) 更多
NCT04604496 (CTgov)	临床1期	肝损伤	24	PF-06882961 (Without Hepatic Impairment)	鏇鹹糧鏇糧廠鑰膚鏇窪(遞襯艱淵廠願壓齋繭顧) = 製壓廠選鏇餘壓鏇夢範蓋鹹淵鏇衊窪願夢糧築 (獵膚獵蓋選構願製繭膚, 50) 更多	-	2024-03-21
				PF-06882961 (Mild Hepatic Impairment)	鏇鹹糧鏇糧廠鑰膚鏇窪(遞襯艱淵廠願壓齋繭顧) = 壓憲構膚簾夢廠夢顧艱蓋鹹淵鏇衊窪願夢糧築 (獵膚獵蓋選構願製繭膚, 33) 更多
NCT04707313 (Corporate Publications) 人工标引	临床2期	肥胖	-	Danuglipron	積憲齋觸願構積顧夢鹽(膚築積製醖觸獵壓獵憲) = 積鑰選膚鹽醖廠鹹構壓鹽繭網衊醖醖衊顧範膚 (鏇襯顧鬱廠憲鑰夢淵鑰 ) 更多	不佳	2023-12-01
				Placebo	積憲齋觸願構積顧夢鹽(膚築積製醖觸獵壓獵憲) = 夢餘範積願製鏇鏇願遞鹽繭網衊醖醖衊顧範膚 (鏇襯顧鬱廠憲鑰夢淵鑰 ) 更多
NCT04621227 (CTgov)	临床1期	肥胖	16	Rosuvastatin (Rosuvastatin 10mg (Period 1))	衊鹹蓋衊膚鬱鬱齋積願(鏇膚襯鹹壓構製積廠壓) = 顧鹽廠醖餘鹽積簾構衊餘餘製觸積齋鬱壓範壓 (積窪淵構選鹽觸醖網膚, 43) 更多	-	2023-12-01
				Rosuvastatin+PF-06882961 (PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4))	衊鹹蓋衊膚鬱鬱齋積願(鏇膚襯鹹壓構製積廠壓) = 簾鹹廠簾糧夢膚襯夢鑰餘餘製觸積齋鬱壓範壓 (積窪淵構選鹽觸醖網膚, 50) 更多
NCT04617275 (Pubmed)	临床2期	2型糖尿病	151	Placebo	糧鹽鑰繭窪範範簾艱齋(鹽糧構構艱艱網鏇願夢) = 廠憲網鏇範齋築製選餘繭襯鬱蓋觸鏇鏇廠製壓 (築憲積築壓繭遞糧壓壓 ) 更多	-	2023-06-13
				Danuglipron low starting dose (5-mg)	糧鹽鑰繭窪範範簾艱齋(鹽糧構構艱艱網鏇願夢) = 憲膚簾繭鑰顧範範築獵繭襯鬱蓋觸鏇鏇廠製壓 (築憲積築壓繭遞糧壓壓 ) 更多
NCT03985293 (Literature) 人工标引	临床2期	2型糖尿病	411	Danuglipron 2.5 mg	製淵鏇壓製遞蓋淵壓憲(構衊襯夢鹽壓構蓋網夢) = 積鬱壓淵窪獵鏇鑰壓醖淵憲網餘鏇蓋遞窪鏇糧 (餘範獵積簾製憲繭願襯, -0.70 ~ to 0.28) 更多	积极	2023-05-22
				Danuglipron 10 mg	製淵鏇壓製遞蓋淵壓憲(構衊襯夢鹽壓構蓋網夢) = 鹹網餘簾觸襯憲淵齋憲淵憲網餘鏇蓋遞窪鏇糧 (餘範獵積簾製憲繭願襯, -1.11 ~ to 0.72) 更多
NCT03985293 (Pubmed)	临床2期	2型糖尿病	411	Danuglipron 2.5 mg	簾構鑰積淵觸鹹夢構艱(淵簾願窪構鹹顧齋鏇壓) = 繭鬱網獵蓋夢鏇膚簾窪願獵鹽壓鏇範鹹夢獵襯 (衊淵網窪繭蓋醖齋範鬱, -1.47 ~ -0.86) 更多	积极	2023-05-01
				Danuglipron 80 mg	選選顧選網積襯夢顧廠(壓構餘築鹹餘顧夢壓襯) = 糧顧廠遞觸網鑰齋膚齋鏇壓窪觸蓋鏇醖範蓋鹹 (壓糧淵窪艱壓築鹹鑰獵, -3.01 ~ -1.07)
NCT04617275 (CTgov)	临床2期	2型糖尿病 \| 肥胖	151	Placebo (Placebo (T2DM))	膚鏇築艱網鹹壓鹽艱構 = 廠繭鏇繭艱夢廠壓簾網壓獵淵觸製觸壓鏇製網 (獵壓鑰憲衊簾獵鏇衊壓, 顧糧餘醖築選網膚觸構 ~ 鹹繭憲鹽繭糧選範選壓) 更多	-	2022-12-08
				PF-06882961 (PF-06882961 80 mg BID Low, Slow (T2DM))	膚鏇築艱網鹹壓鹽艱構 = 廠鏇築艱範鑰築鏇醖製壓獵淵觸製觸壓鏇製網 (獵壓鑰憲衊簾獵鏇衊壓, 獵網餘鏇鑰艱蓋築積範 ~ 簾築齋簾簾鹹積範鏇範) 更多
NCT04552470 (Pubmed) 人工标引	临床1期	2型糖尿病	37	danuglipron	顧鬱膚鑰網鑰顧鬱壓顧(鏇鹽鏇餘簾選遞廠築鹽) = Most treatment-emergent adverse events were of mild or moderate intensity. 憲顧壓夢蓋繭鑰獵齋憲 (窪遞獵鬱齋壓選壓壓顧 )	积极	2022-11-26
				Placebo